Day: September 10, 2025

Verkkokauppa.com’s upcoming financial reporting and Annual General Meeting in 2026 Verkkokauppa.com Oyj         STOCK EXCHANGE RELEASE        10 September 2025 at 8:00 a.m. EEST Verkkokauppa.com Oyj will publish its upcoming financial reports and financial statements as follows:Financial statements bulletin for the year 2025 on Thursday 12 February 2026 Annual reporting package for 2025, including the Report of the Board of Directors and the Financial Statements, Corporate Governance Statement and Remuneration Report, during the week starting on 9 March (week 11) in 2026 Interim report for January – March 2026 on Thursday 23 April 2026 Half-year financial report for January – June 2026 on Thursday 16 July 2026 Interim report for January – September 2026 on Thursday 22 October 2026 Financial statements bulleting for the year 2026 on Friday...

TGS’ presentation for the Pareto Securities Energy Conference 2025 is available on www.newsweb.no or TGS’ website www.tgs.com. CEO Kristian Johansen will present today at 15:55 CEST. For more information, visit TGS.com or contact: Bård Stenberg VP IR & Communication Mobile: +47 992 45 235 investor@tgs.comAttachmentPareto Securities Energy Conference 2025

Transformation to increase speed and redirect resources to growth opportunities within diabetes and obesity, aiming at reaching millions of untreated patients Intention to reduce ~9,000 roles globally with the expectation to deliver DKK 8bn of annualised savings by the end of 2026 One-off restructuring costs of DKK 8bn leading to an updated full-year 2025 operating profit growth outlook of 4–10% at CERBagsværd, Denmark, 10 September 2025 – Novo Nordisk today announced a company-wide transformation to simplify its organisation, improve the speed of decision-making, and reallocate resources towards the company’s growth opportunities in diabetes and obesity. As part of the transformation, Novo Nordisk intends to reduce the global workforce by approximately 9,000 of the 78,400 positions in the company, with around 5,000 reductions expected...

Coop Pank’s financial results in August 2025:In August, number of the bank’s clients increased by 1,700 and number of active clients decreased by 300. By the end of the month number of clients reached 221,000 and number of active clients reached 103,800. Over the year, customer base has grown by 11%.     Volume of the bank’s customer deposits decreased by 4 million euros and reached 1.92 billion euros by the end of month. Deposits of corporate customers decreased by 6 million euros and deposits of private customers increased by 6 million euros. The volume of deposits attracted from international platforms decreased by 4 million euros. Over the year, volume of bank deposits has grown by 86 million euros, i.e. 5%.   The bank’s loan portfolio increased by 14 million euros and reached 1.98 billion euros by the end of month....

On 9 September 2025, AS LHV Group carried out an issue of Tier 2 subordinated notes in the total nominal amount of EUR 80,000,000 (the “Notes”) in the international markets. The settlement date of the Notes is 16 September 2025. The Notes are issued in bearer form with a denomination of EUR 100,000, with increments of EUR 1,000. The Notes mature on 16 September 2035 and have a first call date on 16 September 2030. Until the first call date, the Notes bear interest at a fixed rate of 5.5% per annum, payable annually. Thereafter, the Notes will bear interest at 3-month Euribor plus a margin of 3.25%, payable quarterly. The issue price of the Notes was 99.817% of the nominal amount, corresponding to a yield of 5.543%. The Notes will be listed on the Global Exchange Market of Euronext Dublin. The Notes were allocated to European investment...

Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes        Approval based on the TN-10 study, demonstrating Tzield’s ability to delay the onset of stage 3 T1D in adult and pediatric patients aged eight years and older, with stage 2 T1D compared to placebo Additional regulatory reviews are ongoing across different disease stages by regulatory authorities around the worldParis, September 10, 2025– The Chinese National Medical Products Administration (NMPA) has approved Tzield (teplizumab) as the first disease-modifying therapy in autoimmune type 1 diabetes (T1D) indicated to delay the onset of stage 3 T1D in adult and pediatric patients aged eight years and older with stage 2 T1D. The review was completed under priority review, following the recognition by NMPA...

Leiden, the Netherlands, September 10, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that it has been promoted from the Euronext AScX® (Small Cap) to the AMX® (MidCap) index, effective from September 22, 2025. Euronext Amsterdam announced the results of its review of the AMX index, which comprises 25 companies based on free-float market capitalization and liquidity. This marks Pharming’s return to the AMX index, reflecting the Company’s strong growth momentum. Fabrice Chouraqui, Chief Executive Officer, commented: “Pharming’s inclusion in the AMX mid cap index reflects our financial and pipeline growth momentum. It will further increase our visibility and attractiveness to investors. Looking forward, we remain focused on executing on our significant commercial and pipeline catalysts...

MCH GROUP INCREASES HALF-YEAR PROFIT AND STRENGTHENS PROFITABILITY  MCH Group closed the first half of 2025 with an increase in earnings. Despite lower revenues, profitability improved further – clear evidence of the implementation of efficiency measures.  For the third consecutive time, following years of losses, MCH Group reported a positive half-year result. Despite a slight decline in revenue, profitability increased markedly: net profit amounted to CHF 5.3 million, operating income to CHF 222.4 million, while EBITDA rose to CHF 18.9 million – an increase of CHF 3.6 million compared to the prior-year period. This confirms the positive impact of MCH Group’s efficiency measures, which streamlined structures and processes and reduced the cost base. At the same time, new opportunities have been opened in Basel and internationally...

Faraday Future Successfully Completes Nasdaq One-Year Compliance Monitoring Period as it Fully Met All Compliance Requirements During the Period, Returns to a Fully Normal Listed-Company StatusFaraday Future Successfully Completes Nasdaq One-Year Compliance Monitoring Period as it Fully Met All Compliance Requirements During the Period, Returns to a Fully Normal Listed-Company StatusUpholding its principles of “no further reverse stock splits” and prudent equity issuances, the Company is committed to protection of stockholder interests.  Over the past year, FF has made significant progress in system development and financial management, as well as advancing its core strategies and businesses, achieving substantial improvements in both business fundamentals and capital fundamentals.  YT Jia executes additional stock purchase under...